Loading…
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-128M | $-125M | $-105M | -38.3% | - | - |
| 2024 | $0M | $-153M | $-162M | $-132M | -38.2% | - | - |
| 2023 | $0M | $-138M | $-125M | $-123M | -39.5% | - | - |
| 2022 | $0M | $-143M | $-243M | $-120M | -59.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 145.45 | 141.53 | 157.09 | 131.41 |
| Operating Income | -145.45 | -141.53 | -157.09 | -131.41 |
| EBITDA | -142.81 | -137.79 | -153.28 | -128.30 |
| EBIT | -145.45 | -141.53 | -157.09 | -131.41 |
| Pretax Income | -242.81 | -125.04 | -161.65 | -124.55 |
| Net Income | -242.81 | -125.04 | -161.65 | -124.55 |
| Net Income Common Stockholders | -242.81 | -125.04 | -161.65 | -124.55 |
| Total Expenses | 145.45 | 141.53 | 157.09 | 131.41 |
| Interest Income | 4.90 | 16.71 | 20.09 | 16.61 |
| Research And Development | 112.46 | 103.82 | 115.36 | 92.85 |
| Selling General And Administration | 32.99 | 37.70 | 41.73 | 38.55 |
| Normalized EBITDA | -40.81 | -137.79 | -130.78 | -118.80 |
| Normalized Income | -140.81 | -125.04 | -139.15 | -115.05 |
| Basic EPS | -1.99 | -0.83 | -0.69 | 0 |
| Diluted EPS | -1.99 | -0.83 | -0.69 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -102 | 0 | -22.50 | -9.50 |
| Total Unusual Items Excluding Goodwill | -102 | 0 | -22.50 | -9.50 |
| Net Income From Continuing Operation Net Minority Interest | -242.81 | -125.04 | -161.65 | -124.55 |
| Reconciled Depreciation | 2.64 | 3.73 | 3.81 | 3.11 |
| Net Interest Income | 4.90 | 16.71 | 20.09 | 16.61 |
| Net Income From Continuing And Discontinued Operation | -242.81 | -125.04 | -161.65 | -124.55 |
| Total Operating Income As Reported | -247.45 | -141.53 | -179.59 | -140.91 |
| Diluted Average Shares | 122.02 | 150.18 | 233.82 | 0 |
| Basic Average Shares | 122.02 | 150.18 | 233.82 | 0 |
| Diluted NI Availto Com Stockholders | -242.81 | -125.04 | -161.65 | -124.55 |
| Net Income Including Noncontrolling Interests | -242.81 | -125.04 | -161.65 | -124.55 |
| Net Income Continuous Operations | -242.81 | -125.04 | -161.65 | -124.55 |
| Other Income Expense | -102.26 | -0.23 | -24.66 | -9.75 |
| Other Non Operating Income Expenses | -0.26 | -0.23 | -2.16 | -0.25 |
| Special Income Charges | -102 | 0 | -22.50 | -9.50 |
| Other Special Charges | 102 | 0 | 22.50 | 9.50 |
| Net Non Operating Interest Income Expense | 4.90 | 16.71 | 20.09 | 16.61 |
| Interest Income Non Operating | 4.90 | 16.71 | 20.09 | 16.61 |
| General And Administrative Expense | 32.99 | 37.70 | 41.73 | 38.55 |
| Other Gand A | 32.99 | 37.70 | 41.73 | 38.55 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Erasca, Inc.this co. | ERAS | $2.8B | - | 7.96 | -38.3% | -20.28 |
| Denali Therapeutics Inc. | DNLI | $3.0B | - | 2.87 | -50.6% | -3.93 |
| Alumis Inc. | ALMS | $2.9B | - | 7.95 | -80.8% | -6.02 |
| LifeStance Health Group, Inc. | LFST | $2.9B | 371.50 | 1.90 | 0.6% | 39.06 |
| Dyne Therapeutics, Inc. | DYN | $2.9B | - | 2.95 |
| -45.9% |
| -4.14 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.8B | - | 14.56 | -8.5% | -352.93 |
| Haemonetics Corporation | HAE | $2.7B | 16.26 | 3.03 | 20.4% | 9.88 |
| Soleno Therapeutics, Inc. | SLNO | $2.7B | 135.33 | 6.13 | 4.6% | 145.68 |
| Kodiak Sciences Inc. | KOD | $2.7B | - | 17.11 | -146.1% | -11.78 |
| Peer Median | - | 135.33 | 4.58 | -27.2% | -4.04 | |